August 02, 2017 | Joanne Morrison
Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
University of Maryland School of Medicine
Director of Marketing and Public Relations
University of Maryland School of Medicine
Tuesday, August 09, 2022
A new study, published in The Lancet Global Health, finds typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to 3 years in children as young as 9 months old in Malawi. The research – conducted by the Blantyre Malaria Project, Malawi-Liverpool-Wellcome Trust, and researchers at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) – found that the TCV vaccine is safe and well tolerated. Importantly, the vaccine can be given to 9-month-old infants at the same time as routine measles-rubella vaccinations without reducing the immune response to either vaccine.
Friday, May 20, 2022
University of Maryland School of Medicine (UMSOM)’s Institute of Human Virology (IHV) researchers received funding from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) for $2.7 million to study genetic changes in two genes from the HIV-1 virus that may make it resistant to antiretroviral therapy. The study, named INSPIRE, will analyze genetic variation in types of HIV circulating in a handful of African countries that will help to better understand the implications of these mutations and will improve clinical management of patients.
Thursday, September 16, 2021
First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever
A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV.
Tuesday, July 06, 2021
UM School of Medicine Researchers Receive NIH Avant-Garde Award for Out-Of-Box Concept to Cure HIV and Treat Co-Existing Addiction
Linda Chang, MD, MS, Professor of Diagnostic Radiology & Nuclear Medicine at the University of Maryland School of Medicine (UMSOM), received the National Institute on Drug Abuse (NIDA) 2021 Avant-Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research — a National Institutes of Health (NIH) Director’s Pioneer Award. This prestigious award supports researchers with exceptional creativity, who propose high-impact research with the potential to be transformative to the field.
Monday, June 24, 2019
UM School of Medicine's Institute of Human Virology Awarded $40 Million Grant to Conduct HIV Population Surveys
Man Charurat, MD, Professor of Medicine, Director, Center for International Health, Education, and Biosecurity (CIHEB), and Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), has been awarded a five-year grant from the U.S. Centers for Disease Control and Prevention (CDC) to conduct HIV population-based HIV impact assessments worldwide to measure the progress towards the control of the HIV epidemic
Friday, September 22, 2017
Malaria is a major cause of death for children throughout sub-Saharan Africa. In this high transmission area, they are at risk of severe malaria early in life when their immune system has not developed enough to protect them.
Monday, March 20, 2017
Pediatric Infectious Disease Specialist, Dr. Miriam Laufer, to Head Division of Malaria Research at the University of Maryland School of Medicine
Christopher Plowe, MD, MPH, the Frank M. Calia Professor of Medicine at the University of Maryland School of Medicine (UM SOM), and director of the UM SOM Institute for Global Health (IGH), as well as UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Miriam K. Laufer, MD, MPH, will be the new Director of the Division of Malaria Research (DMR) at IGH.
Tuesday, October 25, 2016
As the new Administration is presented with great challenges facing the United States, one will be a longtime foe, the U.S. HIV/AIDS epidemic. Since President Barack Obama was elected in 2008, I have publicly called on our country’s leaders to utilize the largest global health initiative in history - the President’s Emergency Plan for AIDS Relief (PEPFAR) - as a model to address the U.S. epidemic.